ロード中...

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

Since the advent of immunotherapy revolutionized the treatment of metastatic renal cell carcinoma (mRCC), the attention of oncologists has been unavoidably shifted from tyrosine kinase inhibitors (TKIs) to immune checkpoint blockade, with the associated risk of listing cabozantinib as just one of ma...

詳細記述

保存先:
書誌詳細
出版年:Ther Adv Med Oncol
主要な著者: Bersanelli, Melissa, Buti, Sebastiano
フォーマット: Artigo
言語:Inglês
出版事項: SAGE Publications 2017
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5613858/
https://ncbi.nlm.nih.gov/pubmed/28974985
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834017724314
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!